The U.S. healthcare system faces a significant challenge: balancing financial incentives with the need for personalized patient care. Although financial incentives are critical for the sustainability of healthcare institutions, they often conflict with the goal of providing individualized
Health Information Exchanges (HIEs) have been hailed as a transformative innovation in the medical field, promising to improve patient care by making health data accessible to all involved healthcare providers. However, the reality of HIEs presents a more complex picture. While the idea of a
The healthcare industry is on the brink of a significant transformation in 2024 with the rapid adoption of advanced technologies and innovative data analytics strategies. Patient care is set to become more personalized, efficient, and proactive, significantly enhancing the quality of care while
Gene therapy has ushered in a new era of medical possibilities, offering groundbreaking treatments for debilitating and often fatal diseases. One of the most prominent examples is Lenmeldy (atidarsagene autotemcel), a gene therapy developed by Orchard Therapeutics and recently acquired by Kyowa
In a recent turn of events, the National Health Service (NHS) in England has declined to approve the Alzheimer's treatment lecanemab, co-developed by Eisai Co. and Biogen Inc., primarily due to financial considerations. This decision comes despite the drug receiving authorization from the
The modern healthcare landscape is rapidly evolving, with a growing emphasis on patient-centric care. Amidst this transformation, there is a compelling argument that integrating hospitality principles can substantially enhance the healthcare experience. The convergence of these two fields presents
